Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sofosbuvir + velpatasvir + tenofovir alafenamide
- Development stage
- Unknown
- Lead developer
- Gilead Sciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This combination therapy integrates three potent antiviral agents to address Hepatitis C Virus (HCV) and Hepatitis B Virus (HBV) co-infection. Sofosbuvir is a nucleotide analog that inhibits the HCV NS5B RNA-dependent RNA polymerase, acting as a chain terminator. Velpatasvir is a pangenotypic inhibitor of the HCV NS5A protein, essential for viral replication and assembly. Tenofovir alafenamide (TAF) is a prodrug of tenofovir that inhibits HBV reverse transcriptase. Developed in clinical trials by The First Hospital of Peking University using Gilead Sciences' components, this regimen aims to achieve HCV cure while simultaneously suppressing HBV replication, thereby mitigating the risk of HBV reactivation during HCV treatment.
- Other names
- Sof/Vel/TAF
02
Targets
NS5B (Hepatitis C virus non-structural protein 5B (NS5B) RNA-dependent RNA polymerase)Human immunodeficiency virus type 1 reverse transcriptaseHBV Pol (Hepatitis B virus polymerase)NS5A (Hepatitis C virus nonstructural protein 5A (genotype 1b))
Beyond the preview
Go deeper on sofosbuvir + velpatasvir + tenofovir alafenamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sofosbuvir + velpatasvir + tenofovir alafenamide.